NK cell recognition of non-classical HLA class I molecules

Seminars in Immunology

Volumn 12, Issue 2, 2000, Pages 109-119

  López Botet, Miguel ^a   Llano, Manuel ^a   Navarro, Francisco ^a   Bellon, Teresa ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

CD94; HLA E; HLA G; KIR; MICA; NK cell; T lymphocyte

Indexed keywords

CD94 ANTIGEN; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN RECEPTOR; LECTIN RECEPTOR;

ANTIGEN RECOGNITION; CELL LINEAGE; HUMAN; HUMAN CELL; LEUKOCYTE; NATURAL KILLER CELL; REVIEW;

EID: 0242652204     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.2000.0213     Document Type: Article

References (118)

1. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol. 14:1996;619-648.
2. Parham P. NK cells, MHC class I antigens, and missing self. Immunol Rev. 155:1997;1-221.
3. Lanier LL. NK cell receptors. Annu Rev Immunol. 16:1998;359-393.
4. Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol. 10:1998;298-305.
5. López-Botet M, Bellón T. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol. 11:1999;301-307.
6. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 17:1999;875-904.
7. Colonna M, Navarro F, López-Botet M. A novel family of inhib itory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Curr Top Microbiol Immunol. 244:1999;115-122.
8. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. Activating interactions in human NK cell recognition: the role of 2B4- CD48. Eur J Immunol. 29:1999;1676-1683.
9. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol. 162:1999;6981-6985.
10. Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, Bolton W, Ogg G, Boumsell L, Bensussan A. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol. 162:1999;1223-1226.
11. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 7:1997;283-290.
12. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 188:1998;953-960.
13. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogenic or xenogeneic target cells. Eur J Immunol. 29:1999;1656-1666.
14. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med. 189:1999;787-796.
15. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 187:1998;2065-2072.
16. López-Botet M, Carretero M, Bellón T, Pérez-Villar JJ, Llano M, Navarro F. The CD94/NKG2 C-type lectin receptor complex. Curr Top Microbiol Immunol. 230:1998;41-52.
17. Rodríguez A, Carretero M, Glienke J, Bellón T, Ramírez A, Lehrach H, Francis F, López-Botet M. Structure of the human CD94 C-type lectin gene. Immunogenetics. 47:1998;305-309.
18. Boyington J C, Riaz A N, Patamawenu A, Coligan J E, Brooks A G, Sun P D. Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity. 10: 1999;75-82.
19. Carretero M, Palmieri G, Llano M, Tullio V, Santoni A, Geraghty DE, López-Botet M. Specific engagement of the CD94/NKG2A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2A: evidence for receptor function in heterologous transfectants. Eur J Immunol. 28:1998;1280-1291.
20. Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol. 28:1998;264-276.
21. Palmieri G, Tullio V, Zingoni A, Piccoli M, Frati L, López-Botet M, Santoni A. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J Immunol. 162:1999;7181-7188.
22. Cantoni C, Biassoni R, Pende D, Sivori S, Accame L, Pareti L, Semenzato G, Moretta L, Moretta A, Bottino C. The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene. Eur J Immunol. 28:1998;327-338.
23. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 8:1998;693-701.
24. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 391:1998;703-707.
25. Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol. 158:1997;5083-5086.
26. Campbell KS, Cella M, Carretero M, López-Botet M, Colonna M. Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur J Immunol. 28:1998;599-609.
27. Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 391:1998;795-799.
28. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 187:1998;7813-7818.
29. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, Geraghty D. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA. 95:1998;5199-5204.
30. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol. 160:1998;4951-4960.
31. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol. 27:1997;1164-1169.
32. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol. 8:1998;1-10.
33. O'Callaghan CA, Tormo J, Willcox BE, Braud VM, Jakobsen BK, Stuart DI, McMichael AJ, Bell JI, Jones EY. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell. 1:1998;531-541.
34. Valés-Gómez M, Reyburn HT, Erskine RA, López-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 18:1999;4250-4260.
35. Furukawa H, Yabe T, Akaza T, Tadokoro K, Tohma S, Inoue T, Tokunaga K, Yamamoto K, Geraghty DE, Juji T. Cell surface expression of HLA-E molecules on PBMC from a TAP1- deficient patient. Tissue Antigens. 53:1999;292-295.
36. Brooks AG, Borrego F, Posch PE, Patamawenu A, Scorzelli CJ, Ulbrecht M, Weiss EH, Coligan JE. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol. 162:1999;305-313.
37. Navarro F, Llano M, Bellón T, Colonna M, Geraghty DE, López-Botet M. The ILT2 (LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol. 29:1999;277-283.
38. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA, McM ichael AJ, Braud VM. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med. 189:1999;1149-1156.
39. Berg SF, Dissen E, Westgaard IH, Fossum S. Two genes in the rat homologous to human NKG2. Eur J Immunol. 28:1998;444-450.
40. Ho EL, Heusel JW, Brown MG, Matsumoto K, Scalzo AA, Yokoyama WM. Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci USA. 95:1998;6320-6325.
41. Vance RE, Tanamachi DM, Hanke T, Raulet DH. Cloning of a mouse homolog of CD94 extends the family of C-type lectins on murine natural killer cells. Eur J Immunol. 27:1997;3236-3241.
42. Dissen E, Berg SF, Westgaard IH, Fossum S. Molecular characterization of a gene in the rat homologous to human CD94. Eur J Immunol. 27:1997;2080-2086.
43. Lohwasser S, Hande P, Mager DL, Takei F. Cloning of murine NKG2A, B and C second family of C-type lectin receptors on murine NK cells. Eur J Immunol. 29:1999;755-761.
44. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J Exp Med. 188:1998;1841-1848.
45. Salcedo M, Bousso P, Ljunggren HG, Kourilsky P, Abastado JP. The Qa-1b molecule binds to a large subpopulation of murine NK cells. Eur J Immunol. 28:1998;4356-4361.
46. Bai A, Broen J, Forman J. The pathway for processing leader-derived peptides that regulate the maturation and expression of Qa-1b. Immunity. 9:1998;413-421.
47. DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Dominance of a single peptide bound to the class I(B) molecule, Qa-1b. J Immunol. 158:1997;2183-2191.
48. Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell. 79:1994;649-658.
49. Kurepa Z, Hasemann CA, Forman J. Qa-1b binds conserved class I leader peptides derived from several mammalian species. J Exp Med. 188:1998;973-978.
50. Bouwer HG, Seaman MS, Forman J, Hinrichs DJ. MHC class Ib-restricted cells contribute to antilisterial immunity: evidence for Qa-1b as a key restricting element for Listeria-specific CTLs. J Immunol. 159:1997;2795-2801.
51. Tompkins SM, Kraft JR, Dao CT, Soloski MJ, Jensen PE. Transporters associated with antigen processing (TAP)-independent presentation of soluble insulin to alpha/beta T cells by the class Ib gene product, Qa-1(b). J Exp Med. 188:1998;961-971.
52. Llano M, Lee N, Navarro F, Garcia P, Albar JP, Geraghty DE, López-Botet M. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 28:1998;2854-2863.
53. Valés-Gómez M, Reyburn HT, Mandelboim M, Strominger JL. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. [published erratum appears in Immunity 1998, 9:892] Immunity. 9:1998;337-344.
54. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 7:1997;739-751.
55. Miller DM, Sedmak DD. Viral effects on antigen processing. Curr Opin Immunol. 11:1999;94-99.
56. Schust DJ, Tortorella D, Seebach J, Phan C, Ploegh HL. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp Med. 188:1998;497-503.
57. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 10:1999;661-671.
58. Le Gall S., Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, Schwartz O. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity. 8:1998;483-495.
59. Ulbrecht M, Modrow S, Srivastava R, Peterson PA, Weiss EH. Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J Immunol. 160:1998;4375-4385.
60. Cotterill LA, Stauss HJ, Millrain MM, Pappin DJ, Rahman D, Canas B, Chandler P, Stackpoole A, Simpson E, Robinson PJ, Dyson PJ. Qa-1 interaction and T cell recognition of the Qa-1 determinant modifier peptide. Eur J Immunol. 27:1997;2123-2132.
61. Bellón T, Heredia AB, Llano M, Minguela A, Rodríguez A, López-Botet M, Aparicio P. Triggering of effector functions on a CD8+ T cell clone upon the aggregation of an activatory CD94/kp39 heterodimer. J Immunol. 162:1999;3996-4002.
62. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 285:1999;727-729.
63. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 285:1999;730-732.
64. Wagtmann N, Rojo S, Eichler E, Mohrenweiser H, Long EO. A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors. Curr Biol. 7:1997;615-618.
65. Wilson MJ, Torkar M, Trowsdale J. Genomic organization of a human killer cell inhibitory receptor gene. Tissue Antigens. 49:1997;574-579.
66. Selvakumar A, Steffens U, Palanisamy N, Chaganti RS, Dupont B. Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103. Tissue Antigens. 49:1997;564-573.
67. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity. 7:1997;753-763.
68. Mandelboim O, Reyburn HT, Sheu EG, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The binding site of NK receptors on HLA-C molecules. Immunity. 6:1997;341-350.
69. Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, Lanier LL, Parham P. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol. 158:1997;5237-5241.
70. Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO, Wiley DC. Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors [published erratum appears in Nature 1997 Nov 20;390(6657):315]. Nature. 389:1997;96-100.
71. Maenaka K, Juji T, Stuart DI, Jones EY. Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Structure. 7:1999;391-398.
72. Snyder GA, Brooks AG, Sun PD. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Natl Acad Sci USA. 96:1999;3864-3869.
73. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol. 158:1997;4026-4028.
74. Fan QR, Wiley DC. Structure of human histocompatibility leukocyte antigen (HLA)-Cw4, a ligand for the KIR2D natural killer cell inhibitory receptor. J Exp Med. 190:1999;113-123.
75. Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 6:1997;655-661.
76. Vivier E, Daëron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol Today. 18:1997;286-291.
77. Burshtyn DN, Lam AS, Weston M, Gupta N, Warmerdam PA, Long EO. Conserved residues amino-terminal of cytoplasmic tyrosines contribute to the SHP-1-mediated inhibitory function of killer cell Ig-like receptors. J Immunol. 162:1999;897-902.
78. Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, Moretta L, Moretta A. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol. 27:1997;3095-3099.
79. Valés-Gómez M, Reyburn HT, Erskine RA, Strominger J. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci USA. 95:1998;14326-14331.
80. Le Bouteiller P, Blaschitz A. The functionality of HLA-G is emerging. Immunol Rev. 167:1999;233-244.
81. Lee N, Malacko AR, Ishitani A, Chen MC, Bajorath J, Marquardt H, Geraghty DE. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity. 3:1995;591-600.
82. Onno M, Guillaudeux T, Amiot L, Renard I, Drenou B, Hirel B, Girr M, Semana G, Le Bouteiller P, Fauchet R. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol. 41:1994;79-86.
83. Le Bouteiller P, Lenfant F. Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story. Res Immunol. 147:1996;301-313.
84. Parham P. Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Am J Reprod Immunol. 34:1995;10-19.
85. Carosella ED, Dausset J, Kirszenbaum M. HLA-G revisited. Immunol Today. 17:1996;407-409.
86. King A, Hiby SE, Verma S, Burrows T, Gardner L, Loke YW. Uterine NK cells and trophoblast HLA class I molecules. Am J Reprod Immunol. 37:1997;459-462.
87. King A, Burrows T, Loke YW. Human uterine natural killer cells. Nat Immunol. 15:1996;41-52.
88. Verma S, King A, Loke YW. Expression of killer cell inhibitory receptors on human uterine natural killer cells. Eur J Immunol. 27:1997;979-983.
89. Hiby SE, King A, Sharkey AM, Loke YW. Human uterine NK cells have a similar repertoire of killer inhibitory and activatory receptors to those found in blood, as demonstrated by RT-PCR and sequencing. Mol Immunol. 34:1997;419-430.
90. Dorfman JR, Zerrahn J, Coles MC, Raulet DH. The basis for self-tolerance of natural killer cells in beta2-microglobulin- and TAP-1-mice. J Immunol. 159:1997;5219-5225.
91. Zimmer J, Donato L, Hanau D, Cazenave JP, Tongio MM, Moretta A, de la Salle H. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 187:1998;117-122.
92. Avril T, Jarousseau AC, Watier H, Boucraut J, Le BP, Bardos P, Thibault G. Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism. J Immunol. 162:1999;5902-5909.
93. Ober C, Aldrich C, Rosinsky B, Robertson A, Walker MA, Willadsen S, Verp MS, Geraghty DE, Hunt JS. HLA-G1 protein expression is not essential for fetal survival. Placenta. 19:1998;127-132.
94. Munz C, Holmes N, King A, Loke YW, Colonna M, Schild H, Rammensee HG. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J Exp Med. 185:1997;385-391.
95. Mandelboim O, Pazmany L, Davis DM, Valés-Gómez M, Reyburn HT, Rybalov B, Strominger JL. Multiple receptors for HLA-G on human natural killer cells. Proc Natl Acad Sci USA. 94:1997;14666-14670.
96. Pérez-Villar JJ, Melero I, Navarro F, Carretero M, Bellón T, Llano M, Colonna M, Geraghty DE, López-Botet M. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol. 158:1997;5736-5743.
97. Pende D, Sivori S, Accame L, Pareti L, Falco M, Geraghty D, Le Bouteiller P, Moretta L, Moretta A. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. Eur J Immunol. 27:1997;1875-1880.
98. Söderström K, Corliss B, Lanier LL, Phillips JH. CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells. J Immunol. 159:1997;1072-1075.
99. Cantoni C, Verdiani S, Falco M, Pessino A, Cilli M, Conte R, Pende D, Mikaelsson MS, Moretta L, Biassoni R. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. Eur J Immunol. 28:1998;1980-1990.
100. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 189:1999;1093-1100.
101. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C, Bertone S, Moretta A, Moretta L, Mingari MC. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci USA. 96:1999;5674-5679.
102. Chumbley G, King A, Robertson K, Holmes N, Loke YW. Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. Cell Immunol. 155:1994;312-322.
103. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA. 94:1997;11520-11525.
104. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA. 94: 1997;5249-5254.
105. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol. 27:1997;660-665.
106. Colonna M, Navarro F, Bellón T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 186:1997;1809-1818.
107. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 7:1997;273-282.
108. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol. 159:1997;5192-5196.
109. Torkar M, Norgate Z, Colonna M, Trowsdale J, Wilson MJ. Isotypic variation of novel immunoglobulin-like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex. Eur J Immunol. 28:1998;3959-3967.
110. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol. 162:1999;5-8.
111. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol. 160:1998;3096-3100.
112. Vitale M, Castriconi R, Parolini S, Pende D, Hsu ML, Moretta L, Cosman D, Moretta A. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1+NK cell clones. Int Immunol. 11:1999;29-35.
113. Banham AH, Colonna M, Cella M, Micklem KJ, Pulford K, Willis AC, Mason DY. Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukocyte Biol. 65:1999;841-845.
114. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH, Lanier LL. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog [published erratum appears in J Exp Med 1998 Aug 3;188(3):following 614]. J Exp Med. 187:1998;1681-1687.
115. Cosman D, Fanger N, Borges L. Human cytomegalovirus, MHC class-I and inhibitory signalling receptors: more questions than answers. Immunol Rev 168: 17785:1999;177-185.
116. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol. 28:1998;3423-3434.
117. King A, Boocock C, Sharkey AM, Gardner L, Beretta A, Siccardi AG, Loke YW. Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. J Immunol. 156:1996;2068-2076.
118. McMaster M, Zhou Y, Shorter S, Kapasi K, Geraghty D, Lim KH, Fisher S. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol. 160:1998;5922-5928.